The identification of a loss of function SNP in the gene encoding Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) that reduced the risk for CAD and myocardial infarction by reducing LDL levels [11], led to the development of a monoclonal antibody therapy that targets the functional protein to treat hypercholesterolemia, which has shown success in statin-intolerant patients [12]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.